14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs KURA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Overall Winner
6-Pillar Tally: AVDL 4 – 1 KURA (1 Tie)
Matrix Metrics: AVDL 8 – 1 KURA
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas KURA carries 72.4/100 (BUY) at $6.91 (N/M Forward P/E, -394.3% operating margin).
Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AVDL 62.9/100 BUY), AVDL captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.5% vs. -394.3% operating margin) and revenue trajectory (+54.9% vs. +10.1% YoY).
Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs KURA. Trailing 12-month operating profitability (AVDL 2.5% vs KURA -394.3%) and valuation multiples (AVDL 28.8x vs KURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
KURA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $675.3M market capitalization and -394.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs KURA Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas KURA carries 72.4/100 (BUY) at $6.91 (N/M Forward P/E, -394.3% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AVDL 62.9/100 BUY), AVDL captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.5% vs. -394.3% operating margin) and revenue trajectory (+54.9% vs. +10.1% YoY). Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with KURA at +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $79M for KURA. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KURA.
AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.1x EV/Revenue (-112.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus KURA (-224.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, KURA carries 120.5% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 107% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.